Lidocain/Adrenalin Aguettant (Epinephrine, Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on nerve membranes, preventing the generation and conduction of action potentials. This interruption stops pain signals from reaching the brain, producing a rapid and reversible loss of sensation at the injection site.

The specific dose and volume are determined by the prescribing clinician based on the type of procedure, patient weight, and maximum allowable lidocaine dose with epinephrine. Healthcare professionals calculate the appropriate amount to ensure safety and efficacy.

Safety data for this combination in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Adding epinephrine to lidocaine creates vasoconstriction, which reduces systemic absorption, prolongs the anesthetic effect, and minimizes intra‑operative bleeding. Plain lidocaine provides a shorter duration of action and does not offer the same hemostatic benefit.

Store the product below 25 °C in its original packaging, protected from light and moisture. Do not freeze. Inspect the solution for particulate matter or discoloration before use, and discard if any abnormalities are observed.

The medication is supplied as a sterile injectable solution and is administered by a qualified healthcare professional via epidural, infiltration, or perineural injection techniques, following aseptic procedures and the prescribed dosage.

Serious risks include severe allergic reactions (anaphylaxis), cardiac arrhythmias, seizures, and profound hypotension. Immediate medical attention is required if any of these events occur during or after administration.

Patients with known hypersensitivity to lidocaine, other amide‑type local anesthetics, or epinephrine, as well as those with uncontrolled hypertension, severe cardiac disease, or certain arrhythmias, should not receive this product unless a risk‑benefit assessment justifies its use.